Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo by Silvia Gómez-Sebastián et al.
Gómez-Sebastián et al. BMC Biotechnology 2012, 12:59
http://www.biomedcentral.com/1472-6750/12/59RESEARCH ARTICLE Open AccessRotavirus A-specific single-domain antibodies
produced in baculovirus-infected insect larvae are
protective in vivo
Silvia Gómez-Sebastián1, Maria C Nuñez1, Lorena Garaicoechea2, Carmen Alvarado1, Marina Mozgovoj2,
Rodrigo Lasa1, Alan Kahl2, Andres Wigdorovitz2, Viviana Parreño2* and José M Escribano3*Abstract
Background: Single-domain antibodies (sdAbs), also known as nanobodies or VHHs, are characterized by high
stability and solubility, thus maintaining the affinity and therapeutic value provided by conventional antibodies.
Given these properties, VHHs offer a novel alternative to classical antibody approaches. To date, VHHs have been
produced mainly in E. coli, yeast, plants and mammalian cells. To apply the single-domain antibodies as a
preventive or therapeutic strategy to control rotavirus infections in developing countries (444,000 deaths in children
under 5 years of age) has to be minimized their production costs.
Results: Here we describe the highly efficient expression of functional VHHs by the Improved Baculovirus
Expression System (IBESW technology), which uses a baculovirus expression vector in combination with Trichoplusia
ni larvae as living biofactories. Two VHHs, named 3B2 and 2KD1, specific for the inner capsid protein VP6 of Group
A rotavirus, were expressed in insect larvae. The IBESW technology achieved very high expression of 3B2 and 2KD1,
reaching 2.62% and 3.63% of the total soluble protein obtained from larvae, respectively. These expression levels
represent up to 257 mg/L of protein extract after insect processing (1 L extract represents about 125 g of insect
biomass or about 375 insect larvae). Larva-derived antibodies were fully functional when tested in vitro and in vivo,
neutralizing Group A rotaviruses and protecting offspring mice against rotavirus-induced diarrhea.
Conclusions: Our results open up the possibility of using insects as living biofactories (IBESW technology) for the
cost-efficient production of these and other fully functional VHHs to be used for diagnostic or therapeutic purposes,
thereby eliminating concerns regarding the use of bacterial or mammalian cells. To the best of our knowledge, this
is the first time that insects have been used as living biofactories to produce a VHH molecule.
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Conventional antibodies are complex molecules that con-
sist of heavy and light chains. They contain an N-linked
oligosaccharide attached to the second heavy-chain con-
stant domain (CH2), which is essential for antibody func-
tionality. Isolated heavy and light chains can retain
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distribution, and reproduction in any mediumand solubility are reduced. Antibody production in heterol-
ogous expression systems is often cumbersome [1]. In this
regard, a major scientific breakthrough was the discovery
of heavy-chain antibodies. These are produced by camelids
(bactrian camels, dromedaries, llamas and alpacas) and are
functional antibodies devoid of light chains [2]. Camelid
heavy-chain antibodies also lack the CH1 domain, which
interacts with the light chain in conventional antibodies.
Their single N-terminal domain (VHH) binds antigen
without requiring domain pairing and it is the smallest
domain with antigen-binding properties.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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siderably thanks to their ease of manipulation, high affinity
and stability and the well-established methods to generate
antigen-specific VHH antibody libraries. Furthermore,
some of these molecules remain functional after incuba-
tion at high temperature. This characteristic may be
attributed to their efficient refolding after chemical or
thermal denaturalization, which may occur as a result of
increased hydrophilicity in their amino acid sequence [3].
Because of their small size (about 15 kDa) and the
capacity of the extended CDR3 loop to penetrate very
small sites, VHHs can also recognize active enzymatic
sites [4]. Thus VHHs not only pass the renal filter, thus
resulting in rapid blood clearance (serum half-life of about
2 h), but also show rapid tissue penetration.
VHH antibody fragments are emerging as new versatile
reagents for the diagnosis and therapy of infectious dis-
eases, including Rotavirus-induced diarrhea [5-7]. Rotavirus
(RV) is estimated to cause 111 million episodes of gastro-
enteritis per year, resulting in 444,000 deaths in children
under 5 years of age, and children in developing countries
account for 82% of the deaths caused by this disease
[8]. Currently, there are two licensed vaccines against
RV-induced diarrhea in infants; however, no specific
therapy is yet available.
RVs are classified into seven groups (A to G) on the
basis of the antigenic variation of the inner capsid protein
VP6, Group A (RV A) being the leading cause of acute
gastroenteritis in infants. Group A RVs are further classi-
fied into P and G genotypes/serotypes on the basis of the
genetic and antigenic variation of the outer layer proteins
VP4 and VP7, both inducing the neutralizing antibodies
associated with protection. This neutralization is due to
the inhibition of virus binding to integrins [9]. Despite
the different G and P serotypes, VP6 is a strongly con-
served protein among all Group A RVs (90% amino
acid homology). This structural virus protein is highly
immunogenic and constitutes the target antigen of most
immunodiagnostic tests for Group A RV detection.
Conventional antibodies directed to this protein do
not show neutralizing activity in vitro [10]. However,
inhibition of RV replication by a non-neutralizing RV
VP6-specific IgA has been described [9]. Recently, it has
also been demonstrated that VP6-specific VHHs produced
in E. coli have broad RV neutralizing activity in vitro and
their functionality was further confirmed by in vivo
protection experiments in a neonatal mouse model [5].
The mechanism responsible for the broad neutralization
of these single-domain antibodies in vitro, together with
their protective properties in neonatal mice, is unknown.
However, the effects of these antibodies could be related
to their small size, which would allow a larger range of
interactions with the inner capsid protein VP6 than
conventional antibodies.To date, VHHs have been produced in E. coli, yeast,
plants and mammalian cells [1], and there is only one
example of VHH production in filamentous fungi [11].
It is important to highlight that for oral therapy a pre-
requisite is the elimination of any living organism that
could contaminate or replicate in the intestinal tract of
patients, as well as the removal of any potential contam-
inating toxin that may aggravate the diarrhea. Thus the
production of these antibodies in bacteria could intro-
duce some of the mentioned undesirable factors into the
final product, even after several purification steps. Dis-
carding bacteria fermentation for antibody production
removes the option of one of the most cost-efficient pro-
duction systems available. Therefore the only possibility
to apply the above mentioned VP6-specific VHHs as a
preventive or therapeutic strategy to control RV A in
developing countries is to minimize their production
costs. To achieve this goal, it is critical to explore alter-
native expression platforms that present less risk in
terms of undesirable contaminants of the final products,
considering the disease and administration route used. It
is noteworthy that N-glycosylation of some VHHs con-
tributes to toxin- and virus-neutralizing capacity [12].
The use of eukaryotic expression systems would there-
fore be advantageous for VHH production. The thera-
peutic concept of protective single-domain antibodies
against RV A could be envisaged not only as a conven-
tional medicament but also as an additive to elaborate a
functional food able to reduce the incidence or severity
of severe RV A diarrhea, especially in risk populations
(infants in day care centers, hospitalized children, im-
munosuppressed patients, etc.). Therefore, the choice of
an efficient heterologous expression system, involving
high production efficiency or downstream processing,
would represent a step towards the clinical application
of VHHs.
The baculovirus expression vector system (BEVS) is a
widely used method to efficiently produce functional
recombinant proteins, including any kind of antibodies.
However, the production cost of BEVS is relatively high
when insect cells lines are used because the cell culture
characteristics and linear scalability is complex for thera-
peutic proteins. In addition, the investment in bioreac-
tors is potentially too high when the molecule to be
developed is directed mainly at the markets of developing
countries and will probably be used at high therapeutic
doses administered by the oral route. An economically
efficient alternative to insect cell cultures is the use of
insects as living biofactories. Numerous studies have
demonstrated the cost-efficiency and the scalability of pro-
duction of many recombinant proteins, which include
diagnostic reagents [13-17], vaccines [14,18-26] and thera-
peutic molecules [27], among others. The most used
insect larvae for such purposes is the natural host of
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(AcMNPV), the lepidopter Trichoplusia ni (T. ni). Re-
combinant protein production by the combination of
recombinant baculovirus and this insect larva has been
denominated improved baculovirus expression system
(IBESW). This technology represents one of the best
production alternatives based on baculovirus vectors.
Baculovirus-infected larvae produce high yields of re-
combinant protein (frequently more than one milligram
per insect) at a reduced cost [28] and working in non-
sterile conditions. These larvae provide a final product
with high biosafety standards as animal compounds are
not involved in the production process and neither does
cross-infection in mammals occur between pathogens
infecting this lepidopter [18,20,21,26,29].
Here we successfully applied IBESW technology to express
two VHH antibodies, 2KD1 and 3B2, that show neu-
tralizing and protective activity against various strains
of RV A [5]. Using low recombinant baculovirus doses to
express the VHHs, we produced 1.4 and 1.8 mg/ g of in-
sect biomass of recombinant 3B2 and 2KD1, respectively
(up to 257 mg/L of insect extract). The larva-derived anti-
bodies were fully functional and they neutralized the virus
in vitro and in vivo, in a similar way as the E. coli-derived
molecules did. To the best of our knowledge, this is the
first time that insects have been used as living biofactories
to produce a VHH molecule.Results
Analysis of VHH expression in T. larvae
The capacity of 3B2 and 2KD1 VHH antibodies to
recognize and neutralize RVs belonging to distinct sub-
groups and serotypes (different G/P-type combinations)
in vitro and in vivo has been addressed previously [5].
To study the feasibility of expressing these potential
therapeutic molecules against RV A using the IBESW tech-
nology, we generated and characterized two recombinant
baculoviruses expressing these antibodies (BacMel3B2His
and BacMel2KD1His). The encoding genes for the anti-
bodies were cloned in phase with the mellitin signal
peptide to increase productivity, following previous
descriptions in the literature. We inoculated groups of
100 fifth instar larvae with a range of doses of each
recombinant baculovirus inoculum. The optimal dose
selected for VHH production was 50,000 plaque form-
ing units per larvae (pfu/larva) for 3B2 while for 2KD1
it was 10,000 pfu/larva. The larva-derived recombinant
antibodies were detected in TSP fractions obtained from
infected larvae by Coomassie blue staining of SDS-PAGE
gels and showed the expected electrophoretic mobility
(Figure 1A). Both VHHs expressed in larvae were also
recognized specifically by an anti-VHH polyclonal anti-
body in a Western blot (Figure 1A).Capillary electrophoresis using the Experion system
(Bio-Rad) was used to quantify in triplicate the recom-
binant VHHs produced in optimal conditions in the TSP
fractions obtained from larva infected with each recom-
binant baculovirus. The percentages of recombinant
VHHs produced were 2.62 and 3.63 for 2KD1 and 3B2
respectively (Figure 1B). Recombinant VHHs were puri-
fied by affinity chromatography (Figure 1C) and recovery
rates of around 50% were achieved for both molecules.
In vitro functionality of the larva-derived VHHs
We first analyzed the recognition of the VP6 protein in
the context of the RV A particles obtained in infected
cell cultures. Virus supernatant containing 107 FFU/ml
from MA-104 cells infected with the bovine RV INDI-
ANA (SbI, P[5]G6) was used as antigen in an ELISA.
Larva-derived VHHs (purified 3B2 or 2KD1, 3B2 TSP
and 2KD1 TSP) recognized the viral particles in a similar
way to the purified 2KD1 VHH expressed in E. coli,
which was used as a positive control (Figure 2).
In order to evaluate the neutralization activity of larva-
derived VHHs, recombinant single-domain antibodies
were analyzed in a VN test using serial four-fold dilutions
of antibodies and the Wa human RV strain (SbI, P[8]G1).
Similar patterns of cell protection were obtained along the
serial dilutions tested for all the VHHs analyzed. The two
VHHs purified from larvae, 3B2 and 2KD1, neutralized
more than 90% of RV infection in vitro at similar concen-
trations to their E. coli counterparts ( 0.5 and 2 μg/ml,
respectively) (Figure 3).
When raw extracts from larvae containing 3B2 or
2KD1 were assayed in VN assays, low concentrations of
2 μg/ml or 7.8 μg/ml of antibody, respectively, were also
required to neutralize 90% of virus infectivity. This ob-
servation suggests that other components of the insect
included in the samples assayed did not interfere with
the functionality of the VHHs (Figure 3).
In vivo functionality of larva-derived VHHs
For a further demonstration of the functionality of VHHs
produced in larva, we performed in vivo protection
experiments against RVA in newborn mice. Pups received
a single intragastric dose of 100 μg of each purified VHH
(3B2 or 2KD1) daily for 5 days. On the second day of
VHH administration, animals were challenged with the
murine RV strain ECw, which produced diarrhea in 100%
of the untreated control mice. Challenged pups developed
RV-associated diarrhea 48 h post challenge (hpc). Non-
challenged animals fed TSP from control infected larvae
developed no clinical sign during the experiment, thus in-
dicating that the components of the larvae extracts did
not induce diarrhea per se. At the time point correspond-
ing to the onset of diarrhea, the rate of diarrhea among
groups was statistically analyzed. All groups of mice
Figure 1 Expression of recombinant VHHs in T.ni larvae. A. SDS-PAGE analysis and Coomassie blue staining or Western blot (WB) of total
soluble protein extracts of larvae infected with control baculovirus (lane 1), baculovirus expressing VHH Mel2KD1 (lane 2) or baculovirus
expressing VHH Mel3B2 (lane 3). Western blot was carried out using an anti-VHH polyclonal antibody. The arrow indicates VHH bands. B. Analysis
by capillary electrophoresis (Experion; Bio-Rad) of larvae extracts containing VHHs 3B2 and 2KD1. The arrows indicate the peaks used to
determine the percentage of each recombinant VHH by subtracting the background proteins from the larvae extracts. C. SDS-PAGE analysis and
Coomassie blue staining of recombinant VHHs purified by affinity chromatography.
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significantly higher protection rates against RV-associated
diarrhea than the control groups (treated with 2KA4 non-
neutralizing VHH, larvae extracts containing the irrele-
vant recombinant protein VP6 or TSP from control
baculovirus-infected larvae), which presented severe diar-
rhea at 48 hpc in 100% of pups (Figure 4). Specifically, the
pups treated with purified 3B2 and 2KD1 VHHs showed
significantly higher protection rates against diarrhea (53%
and 61%, respectively) than the control groups (0%) at 48
hpc. In addition, the protective effect was maintained until
the end of the experiment (96 hpc), where 33% of theFigure 2 ELISA detection of rotavirus strain INDIANA (SbI, P[5]G6) usin
from larvae expressing monomeric VHH 3B2 or 2KD1 were tested and com
assay was established at an OD405nm of 0.0664.treated mice in each group remained without diarrhea
(Figure 4A).
To evaluate the protective effect of the VHH treatment
against viral shedding, at the end of the in vivo protec-
tion assays (96 hpc) all pups were euthanized and intes-
tine homogenates were checked by ELISA. Results were
statistically analyzed. Similarly to what was observed for
clinical signs, all groups of pups fed neutralizing VHHs
showed significantly lower rates of viral shedding than
the control groups (Figure 4B). In agreement with the
diarrhea protection, only 53% of pups fed purified 3B2
VHH did not show viral shedding at 96 hpc, while pupsg larva-derived VHHs. Serial dilutions of purified or raw material
pared with the VHH obtained from E. coli. The cut-off point of the
Figure 3 In vitro RV neutralization properties of larva-derived single-domain antibodies determined by a fluorescent focus reduction
assay. Different amounts of VHHs were mixed with 100 fluorescent focus-forming units (FFU) of human RV strain Wa (SbI, P [8]G1). The antibody
concentration that generates an 80% reduction of fluorescent focuses was considered protective. The assay also included 3B2 and 2KD1 purified
from E. coli as positive controls and the total soluble protein of unrelated baculovirus-infected larvae as a negative control.
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tion rate of viral shedding compared with the control
groups as well as with 3B2, where only 6% (1 out of 18)
were positive for RV A by ELISA (Figure 4B).
In a second experiment, we examined whether there was
a synergistic protective effect of both larva-derived purified
3B2 and 2KD1. Interestingly, 60% (4 out of 10) of the pups
treated with 50 μg/dose of each VHH (3B2+2KD1) were
fully protected against diarrhea at 48 and 78 hpc and 50%
(5 out of 10) remained without any clinical sign at 96 hpc
(Figure 4A). Regarding viral shedding, only 30% of the
animals (3 out of 10 mice) presented virus in intestine
samples, showing an intermediate rate of viral shedding
between pups fed each VHH alone (47% and 6%, respect-
ively) but still representing a significant reduction com-
pared with the control groups (100%).(Figure 4B),
With the aim to determine whether raw material from
larvae containing the 3B2 or 2KD1 antibodies was also
protective in mice, two groups of pups were treated with
these extracts, which held identical amounts of VHHs as
tested in the previous experiment using purified anti-
bodies. In this experiment, the number of pups pro-
tected at 48 hpc was lower (50% for neutralizing 3B2
and 2KD1). All animals presented clinical signs of diar-
rhea at later times post infection (Figure 4). In addition,
both groups showed a statistically significant reduction
of viral shedding at 96 hpc, with protection rates of
66.7% (8 out of 12 mice) for 3B2 and 91.7% (11 out of
12 mice) for 2KD1 (Figure 4B).
Discussion
Many novel therapeutic molecules are based on anti-
bodies directed to molecular targets, including infectiouspathogens. These therapeutic antibodies can be pro-
duced in a number of ways while maintaining their anti-
gen affinity properties. However, conventional antibodies
are frequently difficult to produce because of their com-
plex structure. Short versions, such as single-chain anti-
bodies, comprising the antibody-binding domains, lose
some antibody properties and present reduced affinity
and stability. Single-domain antibodies produced by
camelidae have very interesting properties compared to
classical mammalian antibodies as they have only one
variable region (heavy chain), with a reduced size, and
show greater stability under a range of conditions
(Conrath et al., 2005). By a mechanism that is not fully
elucidated and probably related to the small size of 3B2
and 2KD1, the interaction of these antibodies with their
target antigen (the highly antigenically preserved viral
protein VP6) in RV particles differs to that of conven-
tional immunoglobulins. Thus, 3B2 and 2KD1 produce
broad neutralization activity in vitro and are protective
against diarrhea and viral shedding in a neonatal mouse
model. These properties confer these antibodies a high
potential therapeutic value. Experiments to demon-
strate the molecular basis of this mechanism of inter-
action are currently under way.
Monoclonal antibodies are crucial in biopharmaceutical
development and account for 42% of the total market of
biologics. The annual growth of market requirements is
estimated to increase to as much as 25 tons of therapeutic
antibodies per year in 2013. This value would correspond
to an annual growth rate of 37% [30]. This scenario has
driven pharmaceutical companies to identify novel produc-
tion alternatives to conventional fermentation technologies
that facilitate speed of development and production scale-up
Figure 4 Protection against diarrhea and prevention of viral shedding achieved by oral administration of monovalent larva-derived
VHHs 2KD1 or 3B2 in suckling mice challenged with RV. Pups were fed 100 μg (100 μl) of each larva-derived VHH intragastrically from days 0
to 5 once a day. At day 1, the pups were challenged intragastrically with RV 2 h after routine feeding. A. Percentage of pups protected from
diarrhea with 300 DD50 of murine RV ECw at a range of post-infection days. B. Viral shedding was quantified by ELISA in the 10% (wt/vol) small
intestine homogenates. The Fisher exact test was used to compare the proportions of pups with diarrhea and viral secretion among the groups.
Antibody 2KA4 (divalent VHH antibody) or VP6 protein, both also produced in larvae, were used as controls.
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such as plants, transgenic mammalians and insects have
been adapted to produce recombinant proteins of all
kinds, providing excellent results. Today, some of these
methodologies represent true alternatives to the fermenta-
tion of bacteria, yeast, and mammalian or insect cells.
Insect larvae frequently scale up the recombinant pro-
tein production mediated by baculovirus vectors to levelsof grams/L or hundreds of grams/L instead of tens of
milligrams/L usually obtained in insect cells under
fermentation. This technology dramatically reduces the
production costs and fixed investments while also offering
other advantages over classical insect cell fermentation
approaches. First, insects are complex organisms that
contain multiple cell types in perfect physiological condi-
tions for productivity. Complexity frequently increases
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of production based on insects (lepidopters) is unlimited
and fast. Tons of silk thread, composed by two proteins,
are produced by a lepidopter every year and companies
using insects to produce baculoviruses as biopesticides
generate millions of infected insects in short periods of
time by simple procedures. Third, given the flexibility
of baculovirus vectors, the development times implied
by use of insects as living biofactories is very short
when compared to the generation of productive trans-
genic mammalian cell clones.
The first descriptions of insect larvae use as living biofac-
tories emerged in the early ‘90s [31] and several companies
in Europe, USA and Asia currently exploit this technology
using Trichoplusia ni or Bombyx mori lepidopters with
their respective baculovirus vectors. Various kinds of pro-
tein have been successfully expressed in larvae, including
diagnostic reagents [13-17], vaccines [14,18-26,29], thera-
peutic proteins [27], enzymes [32,33], and conventional
complete or fragmented antibodies [34,35]. However, to
the best of our knowledge, this is the first description that
evaluates the efficiency of insects as living biofactories to
express recombinant single-domain antibodies (VHH)
derived from llama. Our results demonstrate that insects
are an efficient alternative to produce fully functional
VHHs, which, in this case, can be used for diagnostic and
therapeutic purposes. The antibodies 3B2 and 2KD1 are
directed to unknown epitopes within the VP6 inner capsid
protein, which is highly immunogenic and conserved
among all Group A RVs, including several subgroup speci-
ficities, various G/P-type combinations, and distinct spe-
cies of origin, as previously demonstrated [5].
These VHH molecules were previously generated func-
tionally in E. coli. However, the use of insect host cells
to produce VHHs would provide further advantages,
such as the possibility to make posttranslational modifi-
cations, including the formation of disulphide bonds
[36]. In this case, llama VHHs, which have an extended
CDR3 that is often stabilized by an additional disulphide
bond with a cysteine residue in CDR2 [1,37], would be
more efficiently produced.
The VHHs expressed in this study were cloned
transcriptionally in phase with the signal peptide of
honey bee mellitin. The incorporation of this signal
peptide to the construct increased the expression
yields, as previously reported with other proteins in
the baculovirus expression system [38], in compari-
son to the use the KDEL ER retention sequence (at
least 200% increase). This signal peptide would allow
the glycosylation of the protein. Although an anom-
alous migration in SDS-PAGE was observed in the
VHH 3B2, this characteristic does not seem to be
caused by this modification more than by another
post-transductional modification since no glycosylationwas detected when using the GLYCOPRO Detection Kit
(Sigma, USA) (data not shown).
The binding capacity of the larva-derived 3B2 and
2KD1 VHHs was compared in a sandwich ELISA with
the same antibodies expressed in E. coli. The binding
behavior was similar in all cases with respect to the RV
viral particles (Figure 2). In addition, both molecules
neutralized Group A RV strain Wa (SbI, P [8]G1) when
they were incubated with the virus (Figure 3). The
capacity of the monomeric VHH to present neutralizing
activity could be related to the small size of these mole-
cules [5]; however, research into the mechanism behind
the RV virus neutralization is still underway.
Furthermore, the intragastric administration of the
VHH 3B2 or 2KD1 in a neonatal mouse model exerted a
protective effect against RV A-induced diarrhea caused by
a highly infectious murine RV, ECw. Fifty-three percent of
the pups treated with purified 3B2 were protected after 48
hpc and at 96 hpc about 35% of the animals were still pro-
tected, and none of these protected animals presented
viral excretion. With the purified 2KD1, 61% of the
animals were protected against diarrhea at 48 hpc and
only one pup showed viral shedding 96 hpc, resulting in
the group with the highest protection rates against RV
infection and disease. Using non-purified larvae crude
extracts containing the VHHs object of this study (TSP),
protection levels were lower compared with their purified
counterparts. However, 66.7% and 91.7% of the animals
presented no viral excretion at 96 hpc by ELISA when
treated with 3B2 TSP or 2KD1 TSP, respectively (Figure 4).
These results were very similar to those previously
obtained when using the same VHHs expressed in E. coli
[5]. The most interesting protective results were obtained
when the 3B2 and 2KD1 VHHs were combined, since
60% of the animals remained protected at 78 hpc and 50%
after 96 hpc. Viral shedding was also dramatically reduced
to 30% in this group (Figure 4). Our results encourage us
to continue to evaluate the protective value of these VHHs
in a larger animal model of RV infection and disease that
more closely resembled the physiology of human infants.
Experiments with the larva-derived VHHs described here
in gnotobiotic pigs are in course.
In conclusion, the monovalent VHHs were efficiently
expressed in larvae and presented the same functionality
as those expressed in E. coli, showing polyreactive prop-
erties against several RV strains (INDIANA (SbI, P[5]
G6), Wa (SbI, P[8]G1) and Ecw) both in ELISA and VN.
These properties were shown to be associated with pro-
tection in a neonatal mouse model. Our results open up
the possibility of using insects as living biofactories for
the cost-efficient production of these and other VHHs
to be used for diagnostic or therapeutic purposes,
thereby eliminating concerns regarding the use of bac-
terial or mammalian cells.
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Control or therapeutic molecules against severe infant
diarrhea produced by rotavirus A are of tremendous
interest due to the number of infection episodes per year
(more than 111 million cases), mainly in children in
developing countries. Two VHHs, named 3B2 and
2KD1, specific for the inner capsid protein VP6 of
Group A rotavirus have been previously characterized as
protective in a rotavirus infection mouse model. A cost-
efficient production is a prerequisite to apply these
single-domain antibodies as a preventive or therapeutic
strategy to control rotavirus A infections in developing
countries. In this work we have modelized the expres-
sion of the above mentioned VHHs by the Improved
Baculovirus Expression System (IBESW technology). This
technology uses a baculovirus expression vector in com-
bination with Trichoplusia ni larvae as living biofactories.
The reached expression levels of VHHs represented up to
257 mg/L of protein extract after insect processing. The
larva-derived antibodies were fully functional when tested
in vitro and in vivo, neutralizing Group A rotaviruses and
protecting offspring mice against rotavirus-induced diar-
rhea. The IBESW technology has the potential to eliminate
many concerns regarding the use of bacterial or mamma-
lian cells, and to our knowledge, this is the first time that
insects have been used as living biofactories to produce a
VHH molecule.
Methods
Construction of recombinant baculoviruses expressing
VHH
The donor vectors were generated as follows, 3B2 or,
2KD1 were PCR-amplified from previously described
and tested pHEN plasmid containing VHH clones of
interest (Garaicoechea et al., 2008) and using the follow-
ing as specific primers:
pVHH1: 50. . .GCTTGGATCCTATGGCTGATGTGCA
GCTGC. . .30
pVHH2: 50. . .CGTATCTAGAGCGGCCGCGTGAGG
AGACG. . .30
pVHH3: 50. . .ACTGTCTAGAGCGGCCGCTGGAGA
C. . .30
pVHH1 and pVHH2 were used for amplification of
the 3B2 VHH, and pVHH1 and pVHH3 for the 2KD1
VHH.
The amplicons were then cloned into the pFast-
MelB2 vector in frame with an insect signal sequence
derived from the honey bee, using the BamHI and
XbaI restriction sites included in the corresponding
primers.
The recombinant baculoviruses BacMel3B2His and
BacMel2KD1His, encoding the VHH molecules 3B2 and2KD1 respectively, were obtained using the Bac-to-Bac™
baculovirus expression system (Invitrogen), following the
manufacturer’s instructions. All constructs incorporated a
His tag sequence at the carboxy terminus of the protein to
facilitate antibody purification.
Infection of insect larvae and Sf21 insect cells
Trichoplusia ni larvae were reared under level 2 biosafety
conditions, as previously described [17]. Groups of 100
fifth instar larvae, between 140–170 mg in weight, were
intraemocelically injected with 5 μl of the doses of the dif-
ferent recombinant baculovirus inocula. Larvae injection
was performed with disposable syringes and using a hand
microapplicator (Burkard Co.UK). Inoculated larvae were
kept at 28°C in specifically designed methacrylate modules
for insect rearing and collected after 72 h post-infection
(hpi). A total of 20 repetitions per treatment (2,000 larvae)
were made. The surviving infected larvae collected per
container were counted and weighed together to obtain
the total biomass recovered per infection dose. Larvae
were then frozen immediately at −28°C until processing.
Spodoptera frugiperda (Sf21) were obtained from Invitro-
gen. This insect cell line derives from the ovarian tissue of
the fall armyworm Spodoptera frugiperda. Sf21 were rou-
tinely grown in TNMFH medium (PAN Biotech) supple-
mented with Foetal Bovine Serum 10% (PAN Biotech,
3302-P101304) and gentamycin sulfate 50 mg/ml (Lonza,
BE02-012E).
Insect protein extract preparation, characterization and
recombinant protein purification
Total soluble protein (TSP) from infected larvae (30 μg/lane)
was extracted as previously described (Perez-Filgueira
et al., 2006) and was analyzed by 15% SDS-PAGE and
stained with Coomassie blue or transferred onto nitro-
cellulose membranes to perform a Western blot using a
polyclonal anti-VHH antibody generated in rabbits [5]
at 1:200 dilution in blocking solution (4% fat free dry
milk in PBS 1X) for 1 h, followed by one wash with
PBS 1X for 15 min and two more washes for 5 min. A
secondary incubation was then carried out for 1 h with
an anti-rabbit IgG, horse radish peroxidase (GE Health-
care) at 1:2000 dilution in blocking solution. Membranes
were developed using ECL reagent and images were
capture by Chemidoc (Bio-Rad) and analyzed using the
Image labTM Software, version 2.0.1 (Bio-Rad).
For quantification, the specific samples were loaded in
Pro260 chips (Bio-Rad) and analyzed by capillary electro-
phoresis using the Experion system (Bio-Rad), following the
manufacturer’s instructions. The Experion system resolved
and quantified protein samples from 10 to 260 kDa in size
with high sensitivity comparable to colloidal Coomassie
blue SDS-PAGE gel staining. Each amount (percentage) of
recombinant protein was obtained by means of direct
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specific TSP extract profile. The control protein extract
(Ni) was used as a “background” subtracted from the esti-
mated area.
Enzyme-Linked ImmunoSorbent Assays (ELISAs) for VHH
characterization
Group A RV ELISA
Sandwich ELISA. Maxisorp plates were coated with a 1/
10,000 dilution of a polyclonal antiserum to RVA obtained
from a gnotobiotic RV-infected pig (kindly supplied by
Dr. LJ Saif, OSU, USA). After blocking plates with 4%
semi-skimmed milk in PBS at pH 7.4, we added 107
FFU/ml of the bovine RV A reference strain INDIANA
(SbI, P[5]G6) or mock-infected MA-104 cells (used as
negative control) to the wells. Plates were blocked with
10% skimmed milk in PBS at pH: 7.4. Serial two-fold
dilutions of the recombinant VHHs were added and
incubated at 37°C for 1 h. Plates were washed four
times in PBS at pH 7.4, 0.05% Tween20, and the VHHs
were detected by incubation for 1 h with a rabbit poly-
clonal anti-VHH (1:7000 diluted in PBS pH 7.4/ 0.05%
Tween20/ 2% skimmed milk solution). ELISA was then
revealed using a horseradish peroxidase-conjugated IgG
anti-rabbit (KPL) and H2O2/ABTS as substrate/chromogen
system. The background (signal given by the mock-infected
cells) was subtracted from each sample. The cut-off point
for the assay was established as mean plus three standard
deviations of the corrected optical density (OD) measured
in the PBS wells (blank). Using this cut-off, the detection
limit of the assay was 0.5 to 0.2 ng/well of functional VHH
specific for RVA.
Viral neutralization assay (VN test)
The fluorescent focus neutralization test was used for
purified VHH molecules, as described previously [39].
Briefly, serial four-fold dilutions of purified VHH mole-
cules were mixed with 100 fluorescent focus-forming units
(FFU) of human RV strain Wa (SbI, P[8]G1), followed by
incubation for 1 h at 37°C. Mixtures were then plated onto
MA-104 monolayers and incubated for 48 h at 37°C. The
plates were fixed with 70% acetone, and RV replication
was detected using a fluorescein-labeled anti-RV anti-
serum made in bovine at a 1/100 dilution. The neutral-
izing activity of VHH is expressed as the minimum
amount of recombinant protein required to decrease the
fluorescent foci produced by 100 FFUs by 80%.
Rotavirus protection assay in neonatal mice
Assays were carried out as previously described [5]. Basic-
ally, groups of four-day-old BALB/c mouse pups received
100 μl of a solution containing 100 μg of recombinant
VHH per dose, via an intragastric gauge, once a day for
5 days, starting on day 0. On day two of the VHHtreatment, pups received 20 μl of 5% bicarbonate solution
followed by intragastric challenge with 300 DD50 of
murine RV strain ECw (a dose causing diarrhea in
100% of control mice). RV-inoculated mice not treated
or treated with VP6 larva extract, and mice treated
with the same amount of a non-neutralizing bivalent
2KA4 VHH were included as controls. Mice fed larvae
infected with wild-type baculovirus and challenged
with murine RV or not challenged were also included
in order to discard the possibility that the larvae
extracts themselves induced diarrhea. Challenges were
conducted in two independent experiments. To detect
induction of diarrhea, pups were clinically evaluated by
direct palpation of the abdomen by a well-trained per-
son working in a blinded fashion with regard to the
treatment groups. As murine RV ECw spread in litter-
mates, cases of diarrhea that developed 24 h later or
more after the first case in a litter were not attributable
to the initial inoculum and therefore were not
considered. At 4 days (96 h post challenge), pups were
euthanized and small intestines were removed, frozen-
thawed, and homogenized in 10% (wt/vol) Hanks
balanced salt solution (HBSS). The homogenates were
assayed for the detection of RV by ELISA (Cornaglia
et al., 1989). The Fisher exact test was used to compare
the proportions of pups with diarrhea and viral shedding
between the experimental groups. Statistical significance
was assessed at p < 0.05.
All animal experiments were performed in accordance
with protocols approved by the Instituto de Virología
(CICVyA) and the INTA Ethical committee (CICUAE)
as stated in the resolution N13/2011.
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